GB669782A - Improved pellets for pharmaceutical use - Google Patents
Improved pellets for pharmaceutical useInfo
- Publication number
- GB669782A GB669782A GB24802/49A GB2480249A GB669782A GB 669782 A GB669782 A GB 669782A GB 24802/49 A GB24802/49 A GB 24802/49A GB 2480249 A GB2480249 A GB 2480249A GB 669782 A GB669782 A GB 669782A
- Authority
- GB
- United Kingdom
- Prior art keywords
- layer
- therapeutic
- gelatin
- pellet
- wax
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
669,782. Pharmaceutical pellets. STRONG, COBB & CO., Inc. Sept. 27, 1949 [Oct. 30, 1948], No. 24802/49. Class 81 (i). A pharmaceutical pellet has an inner therapeutic portion 10, an outer therapeutic portion 12 and a spacing layer 11 therebetween, the nature of said layer being such that the active therapeutic agents of said inner and outer portions are separately released in the body of the patient under pH conditions which are different and favourable thereto. The therapeutic layers may be coated with a protective transition layer of e.g. gelatin, varnish, lacquer or wax (as appropriate to desired pH conditions) and the finished pellet with a final layer 13 of e.g. sugar syrup, as such, or in combination with fillers such as calcium carbonate, talc and calcium pyrophosphate, colours and wax. The spacing layer may be of hard fats, waxes, fattyacids, keratin, salol, shellac, sandarac, lacquers or colloidin. An example is given of a pellet containing pancreatin, bile (including bile salts and acids e.g. sodium taurocholate), an antacid e.g. calcium carbonate, magnesium hydroxide, aluminium hydroxide or magnesium trisilicate and a binder and incipient e.g. acacia, gelatin, tragacanth, starch paste or glucose forming a central therapeutic core, which is coated with a transition layer of gelatin, a spacing layer, a therapeutic layer of pepsin and a weak organic acid such as tartaric or citric acid, if desired with the further addition of rennin, followed by a transition layer and a finishing layer. The pancreatin may be replaced wholly or in part by amilopsin, trypsin or steapsin. Specifications 285,091, [Class 81 (i)], and 638,606 are referred to.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US669782XA | 1948-10-30 | 1948-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
GB669782A true GB669782A (en) | 1952-04-09 |
Family
ID=22072944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB24802/49A Expired GB669782A (en) | 1948-10-30 | 1949-09-27 | Improved pellets for pharmaceutical use |
Country Status (3)
Country | Link |
---|---|
BE (1) | BE491927A (en) |
FR (1) | FR1011528A (en) |
GB (1) | GB669782A (en) |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2811483A (en) * | 1954-12-09 | 1957-10-29 | Pfizer & Co C | Pharmaceutical composition and process for preparing the same |
US2921001A (en) * | 1957-04-16 | 1960-01-12 | Sterling Drug Inc | Multi-layered pill or tablet with indicating lamination |
DE1091289B (en) * | 1956-01-25 | 1960-10-20 | Hans Lowey | Process for the production of an orally used drug form with a longer duration of action |
US2991226A (en) * | 1958-02-03 | 1961-07-04 | Frosst & Co Charles E | Long-acting wax-like talc pillage of penicillin |
US3131123A (en) * | 1959-03-13 | 1964-04-28 | Lab Francais De Therapeutique | Enteric tablets and manufacture thereof |
US3147187A (en) * | 1962-09-10 | 1964-09-01 | Don Hall Lab | Sustained release pharmaceutical |
US3181998A (en) * | 1960-08-12 | 1965-05-04 | Joseph L Kanig | Tablet disintegration |
US3184386A (en) * | 1958-05-02 | 1965-05-18 | Burroughs Wellcome Co | Prolonged action medicinal tablets |
US5019302A (en) * | 1986-03-12 | 1991-05-28 | Washington University Technology Associates, Inc. | Method for granulation |
US20130119301A1 (en) * | 2010-06-15 | 2013-05-16 | University Of South Florida | Method of modulated exothermic chemical systems through phase change materials |
EP2616048A1 (en) * | 2010-11-19 | 2013-07-24 | Curemark, Llc | Preparation and use of combination enzyme and gastrointestinal modulator delivery systems |
US8778335B2 (en) | 2000-08-14 | 2014-07-15 | Curemark, Llc | Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders |
US8815233B2 (en) | 1999-12-17 | 2014-08-26 | Curemark Llc | Method for treating pervasive development disorders |
US8921054B2 (en) | 2000-11-16 | 2014-12-30 | Curemark, Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
US8980252B2 (en) | 2011-04-21 | 2015-03-17 | Curemark Llc | Methods of treatment of schizophrenia |
US9017665B2 (en) | 2008-04-18 | 2015-04-28 | Curemark, Llc | Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same |
US9023344B2 (en) | 2008-03-13 | 2015-05-05 | Curemark, Llc | Method of treating toxemia |
US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
US9061033B2 (en) | 2008-10-03 | 2015-06-23 | Curemark Llc | Methods and compositions for the treatment of symptoms of prion diseases |
US9084784B2 (en) | 2009-01-06 | 2015-07-21 | Curelon Llc | Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces |
US9107419B2 (en) | 2009-01-06 | 2015-08-18 | Curelon Llc | Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces |
US9320780B2 (en) | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
US9345721B2 (en) | 2005-08-30 | 2016-05-24 | Curemark, Llc | Use of lactulose in the treatment of autism |
US9511125B2 (en) | 2009-10-21 | 2016-12-06 | Curemark Llc | Methods and compositions for the treatment of influenza |
US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
US10776453B2 (en) | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
US11016104B2 (en) | 2008-07-01 | 2021-05-25 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
US12226464B2 (en) | 2017-04-10 | 2025-02-18 | Curemark, Llc | Compositions for treating addiction |
-
0
- BE BE491927D patent/BE491927A/xx unknown
-
1949
- 1949-09-27 GB GB24802/49A patent/GB669782A/en not_active Expired
- 1949-10-13 FR FR1011528D patent/FR1011528A/en not_active Expired
Cited By (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2811483A (en) * | 1954-12-09 | 1957-10-29 | Pfizer & Co C | Pharmaceutical composition and process for preparing the same |
DE1091289B (en) * | 1956-01-25 | 1960-10-20 | Hans Lowey | Process for the production of an orally used drug form with a longer duration of action |
US2921001A (en) * | 1957-04-16 | 1960-01-12 | Sterling Drug Inc | Multi-layered pill or tablet with indicating lamination |
US2991226A (en) * | 1958-02-03 | 1961-07-04 | Frosst & Co Charles E | Long-acting wax-like talc pillage of penicillin |
US3184386A (en) * | 1958-05-02 | 1965-05-18 | Burroughs Wellcome Co | Prolonged action medicinal tablets |
US3131123A (en) * | 1959-03-13 | 1964-04-28 | Lab Francais De Therapeutique | Enteric tablets and manufacture thereof |
US3181998A (en) * | 1960-08-12 | 1965-05-04 | Joseph L Kanig | Tablet disintegration |
US3147187A (en) * | 1962-09-10 | 1964-09-01 | Don Hall Lab | Sustained release pharmaceutical |
US5019302A (en) * | 1986-03-12 | 1991-05-28 | Washington University Technology Associates, Inc. | Method for granulation |
US9624525B2 (en) | 1999-12-17 | 2017-04-18 | Curemark, Llc | Method for treating pervasive development disorders |
US8815233B2 (en) | 1999-12-17 | 2014-08-26 | Curemark Llc | Method for treating pervasive development disorders |
US9624526B2 (en) | 1999-12-17 | 2017-04-18 | Curemark Llc | Method for treating pervasive development disorders |
US8778335B2 (en) | 2000-08-14 | 2014-07-15 | Curemark, Llc | Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders |
US9233146B2 (en) | 2000-08-14 | 2016-01-12 | Curemark, Llc | Method of treating and diagnosing Parkinson's disease and related dysautonomic disorders |
US10209253B2 (en) | 2000-11-16 | 2019-02-19 | Curemark, Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
US9377459B2 (en) | 2000-11-16 | 2016-06-28 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
US8921054B2 (en) | 2000-11-16 | 2014-12-30 | Curemark, Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
US9345721B2 (en) | 2005-08-30 | 2016-05-24 | Curemark, Llc | Use of lactulose in the treatment of autism |
US11033563B2 (en) | 2005-08-30 | 2021-06-15 | Curemark, Llc | Use of lactulose in the treatment of autism |
US10350229B2 (en) | 2005-08-30 | 2019-07-16 | Curemark, Llc | Use of lactulose in the treatment of autism |
US9925250B2 (en) | 2008-03-13 | 2018-03-27 | Curemark, Llc | Method of treating proteinuria in pregnancy |
US9023344B2 (en) | 2008-03-13 | 2015-05-05 | Curemark, Llc | Method of treating toxemia |
US11045527B2 (en) | 2008-03-13 | 2021-06-29 | Curemark, Llc | Method of diagnosing preeclampsia or pregnancy-induced hypertension |
US9408895B2 (en) | 2008-03-13 | 2016-08-09 | Curemark, Llc | Method of treating pregnancy-induced hypertension |
US10272141B2 (en) | 2008-04-18 | 2019-04-30 | Curemark, Llc | Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same |
US9017665B2 (en) | 2008-04-18 | 2015-04-28 | Curemark, Llc | Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same |
US9687534B2 (en) | 2008-04-18 | 2017-06-27 | Curemark, Llc | Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same |
US11235038B2 (en) | 2008-04-18 | 2022-02-01 | Curemark, Llc | Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same |
US9320780B2 (en) | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
US10588948B2 (en) | 2008-06-26 | 2020-03-17 | Curemark, Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
US11016104B2 (en) | 2008-07-01 | 2021-05-25 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
US10776453B2 (en) | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
US10413601B2 (en) | 2008-10-03 | 2019-09-17 | Curemark, Llc | Methods and compositions for the treatment of symptoms of prion diseases |
US9687535B2 (en) | 2008-10-03 | 2017-06-27 | Curemark, Llc | Methods and compositions for the treatment of symptoms of prion diseases |
US9061033B2 (en) | 2008-10-03 | 2015-06-23 | Curemark Llc | Methods and compositions for the treatment of symptoms of prion diseases |
US9107419B2 (en) | 2009-01-06 | 2015-08-18 | Curelon Llc | Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces |
US11357835B2 (en) | 2009-01-06 | 2022-06-14 | Galenagen, Llc | Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces |
US9895427B2 (en) | 2009-01-06 | 2018-02-20 | Galenagen, Llc | Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces |
US10736946B2 (en) | 2009-01-06 | 2020-08-11 | Galenagen, Llc | Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces |
US9084784B2 (en) | 2009-01-06 | 2015-07-21 | Curelon Llc | Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces |
US10098844B2 (en) | 2009-04-13 | 2018-10-16 | Curemark, Llc | Enzyme delivery systems and methods of preparation and use |
US9415014B2 (en) | 2009-04-13 | 2016-08-16 | Curemark, Llc | Enzyme delivery systems and methods of preparation and use |
US11419821B2 (en) | 2009-04-13 | 2022-08-23 | Curemark, Llc | Enzyme delivery systems and methods of preparation and use |
US9931302B2 (en) | 2009-04-13 | 2018-04-03 | Curemark , LLC | Enzyme delivery systems and methods of preparation and use |
US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
US9511125B2 (en) | 2009-10-21 | 2016-12-06 | Curemark Llc | Methods and compositions for the treatment of influenza |
US10716835B2 (en) | 2009-10-21 | 2020-07-21 | Curemark, Llc | Methods and compositions for the prevention and treatment of influenza |
US20130119301A1 (en) * | 2010-06-15 | 2013-05-16 | University Of South Florida | Method of modulated exothermic chemical systems through phase change materials |
US9976068B2 (en) * | 2010-06-15 | 2018-05-22 | University Of South Florida | Method of modulated exothermic chemical systems through phase change materials |
US9481821B2 (en) * | 2010-06-15 | 2016-11-01 | University Of South Florida | Method of modulated exothermic chemical systems through phase change materials |
EP2616048A4 (en) * | 2010-11-19 | 2014-04-02 | Curemark Llc | Preparation and use of combination enzyme and gastrointestinal modulator delivery systems |
EP3056197A1 (en) * | 2010-11-19 | 2016-08-17 | Curemark, Llc | Preparation and use of combination enzyme and gastrointestinal modulator delivery systems |
EP2616048A1 (en) * | 2010-11-19 | 2013-07-24 | Curemark, Llc | Preparation and use of combination enzyme and gastrointestinal modulator delivery systems |
US10940187B2 (en) | 2011-04-21 | 2021-03-09 | Curemark, Llc | Method of treatment of schizophreniform disorder |
US8980252B2 (en) | 2011-04-21 | 2015-03-17 | Curemark Llc | Methods of treatment of schizophrenia |
US9492515B2 (en) | 2011-04-21 | 2016-11-15 | Curemark, Llc | Method of treatment of schizophreniform disorder |
US10279016B2 (en) | 2011-04-21 | 2019-05-07 | Curemark, Llc | Method of treatment of schizophreniform disorder |
US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
US11364287B2 (en) | 2012-05-30 | 2022-06-21 | Curemark, Llc | Methods of treating celiac disease |
US12226464B2 (en) | 2017-04-10 | 2025-02-18 | Curemark, Llc | Compositions for treating addiction |
US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
Also Published As
Publication number | Publication date |
---|---|
BE491927A (en) | |
FR1011528A (en) | 1952-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB669782A (en) | Improved pellets for pharmaceutical use | |
GB723945A (en) | An electrolytic process for smoothing and polishing surfaces of gold and gold alloys | |
GB242780A (en) | A preparation for preserving fresh eggs indefinitely | |
GB493934A (en) | Improvements in and relating to methods of treating medicaments | |
GB511827A (en) | Improvements in or relating to ingredients for the manufacture of cosmetics | |
US1124286A (en) | Waterproof glue or cement and method of making the same. | |
CA186047A (en) | Composition for water proofing and preserving leather | |
GLENN et al. | Tinea versicolor. | |
GB122778A (en) | Process for the Manufacture of Easily Soluble Compounds of the C.C.-Dialkyl- C.C.-Diallyl- and C.C.-Alkylaryl Barbituric Acids. | |
GB452115A (en) | Improvements in or relating to toilet powders | |
GB158460A (en) | Improved silver-plating powder | |
GB324859A (en) | Carbon paper and process for its manufacture | |
CA228242A (en) | Production of soluble tanning agent | |
GB617420A (en) | Method of preparing aqueous suspensions of magnesia | |
CA228354A (en) | Launching of ship's life boats | |
GB536801A (en) | Carriers for the application of therapeutically active metal to the body | |
AU2028834A (en) | Improvements in or relating to the preparation of chromic acid and] sparingly soluble chromates | |
GB433142A (en) | Improved manufacture of cosmetic preparations | |
CA230812A (en) | Ship's log | |
GB118182A (en) | Depositing Chromium upon Metals, particularly Iron, Chemically. | |
CA233111A (en) | Manufacture of enamelled writing tablets | |
AU537622A (en) | An improved-windshoot for seagoing' vessels | |
AU101911B2 (en) | Manufacture of oxidising or reducing agents or combined oxidising and reducing agents for promoting the production of oxidising agents more particularly intended for assisting curative metabolic changes in living organisms | |
AU164838A (en) | Improvements in or relating tothe manufacture of coating or impregnating compositions having an aqueous vehicle | |
GB449027A (en) | Improvements in or relating to the manufacture of leather |